Is Enveric Biosciences Stock a good buy in 2025, according to Wall Street analysts?
The consensus among 1 Wall Street analyst covering (NASDAQ: ENVB) stock is to Buy ENVB stock.
Out of 1 analyst, 0 (0%) are recommending ENVB as a Strong Buy, 1 (100%) are recommending ENVB as a Buy, 0 (0%) are recommending ENVB as a Hold, 0 (0%) are recommending ENVB as a Sell, and 0 (0%) are recommending ENVB as a Strong Sell.
What is ENVB's earnings growth forecast for 2025-2025?
(NASDAQ: ENVB) Enveric Biosciences's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.61%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.32%.
Enveric Biosciences's earnings in 2025 is -$9,303,038.
In 2025, ENVB is forecast to generate -$31,884,362 in earnings, with the lowest earnings forecast at -$31,884,362 and the highest earnings forecast at -$31,884,362.
What is ENVB's forecast return on equity (ROE) for 2025-2028?
(NASDAQ: ENVB) forecast ROE is -227.11%, which is considered weak.
What is ENVB's Price Target?
According to 1 Wall Street analyst that have issued a 1 year ENVB price target, the average ENVB price target is $10.00, with the highest ENVB stock price forecast at $10.00 and the lowest ENVB stock price forecast at $10.00.
The Wall Street analyst predicted that Enveric Biosciences's share price could reach $10.00 by Mar 6, 2026. The average Enveric Biosciences stock price prediction forecasts a potential upside of 726.45% from the current ENVB share price of $1.21.
What is ENVB's Earnings Per Share (EPS) forecast for 2025-2025?
(NASDAQ: ENVB) Enveric Biosciences's current Earnings Per Share (EPS) is -$13.36. In 2025, ENVB's EPS is forecast to hit -$12.90 (min: -$12.90, max: -$12.90).
What is ENVB's forecast return on assets (ROA) for 2025-2028?
(NASDAQ: ENVB) forecast ROA is -174.39%, which is lower than the forecast US Biotechnology industry average of 32.43%.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.